Results
H. rhamnoides L. has
a very rich source of fatty acids and omegas. Fatty acids/omegas present
in HR oil are palmitic acid (13.97%), stearic acid (14.76%), oleic
acid (19.94%), linoleic acid (20.357), DHA (31.10%), and traces of
other saturated fatty acids ( Figures 1 and 2 and Table 2 ).
GC-FID analysis of H. rhamnoides L. by GC-FID.
Structures of phytoconstituents present in H. rhamnoides L.
GC-FID analysis of the H. rhamnoides L. chromatogram is given in Figure 1 .
The total phenolic
content of H. rhamnoides L. was 1713
± 0.124 μg/100 g and is mentioned in Table 3 . The TPC is given as gallic acid equivalent
(GAE).
The total flavonoid
content of the H. rhamnoides L. was
310 ± 0.08 μg/100 g and is demonstrated in Table 3 . The TFC is given as quercetin
equivalent (QE).
DPPH scavenging % by H. rhamnoides L. is mentioned in Table 4 . The sample is obtained in
parts per million. Ascorbic acid was used as a reference to compare
the results. The % age inhibition of H. rhamnoides L. is (67.27 μg/mL) in comparison to ascorbic acid (75.34
μg/mL).
Nano-emulsion was prepared successfully and was evaluated by DSC,
TGA, and FTIR. HR oil showed a broad endothermic peak at 160 °C
and a second endothermic peak at 424 °C, as shown in Figure 3 A. PEG 400 showed
a sharp endothermic peak at 112 °C. The cinnamon oil and Tween
80 showed endothermic peaks at 203 and 199 °C, respectively.
The nano-emulsion showed an endothermic peak at 150 C, and no other
peak was observed, indicating the thermal stability of the oil in
formulation. The weight loss of HR oil started at 190 °C and
continued till 500 °C. A rapid weight loss of PEG 400 was observed
between 55 and 95 °C. The weight loss of cinnamon oil started
at 31 °C, and 99% weight loss occurred at 211 °C. The TGA
curve of Tween 80 showed that weight loss started at 32 °C and
continued until 500 °C. The weight loss of nano-emulsion was
only 0.1% at 33 °C, and 50% weight loss was observed at 32 °C,
indicating that the formulation was stable under accelerated temperature
conditions ( Figure 3 B). HR oil showed peaks at 2750, 1680, 1200, and 950 cm –1 due to the presence of the hydroxyl −OH group and alkane
−CH group and the presence of aromatic rings. FTIR of PEG 400
displayed peaks at 3000, 2700, and 1700 cm –1 due
to the CH stretching, CH bending, and C–O–H stretching
vibrations, respectively. The C=O ester group’s stretching
band at 1512 cm –1 and the hydroxyl stretching vibrations’
strong band at 3300 cm –1 were both visible in the
FTIR spectra of Tween 80. The spectrum displays distinctive bands
at 1500–1400 cm –1 owing to alkane deformation,
signals at 1650 cm –1 corresponding to C=C
stretching, and stretching vibrations of C=O groups at 1660–1680
cm –1 . One of the strongest IR absorptions, the carbonyl
stretching absorption is highly helpful in determining the structure
since it allows one to count the amount of carbonyl groups. The FTIR
spectra of SNEDDS showed peaks of the hydroxyl group of HR oil, C=C
stretching of cinnamon oil, C–H bending of PEG 400, and C=O
stretching of Tween 80, indicating the chemical stability of formulation
( Figure 3 C).
Characterization
of H. rhamnoides L. Nano-emulsion (A)
DSC, (B) TGA, and (C) FTIR of HR oil, PEG400,
cinnamon oil, Tween 80, and HR nano-emulsion. DSC of nano-emulsion
showed no endothermic peak, indicating the uniform distribution of
HR oil, and TGA of the final formulation showed a two-step degradation.
Characteristic peaks of HR oil also shown in the FTIR spectra of nano-emulsion
indicated the chemical stability of formulation.
After continuous administration of letrozole for 5
weeks in the disease group, a significant increase ( p < 0.05) was noticed in the body weight of the rats as compared
to the normal control group. The increase in weight of diseased rats
was observed at 20%, and contrarily, control rats’ weight increased
by 13.27% of their starting weight ( Table 5 ).
At the end of the trial period, rats in the diseased
group weighed more than the normal control group. However, the weight
gain of the metformin group was increased in a much similar way as
that of the PCOS group. However, rats from the HR 0.5 g/kg group showed
a rise in body weight as that of the normal control group. The weight
of rats from HR 1 g/kg increased in a parallel manner that is almost
one-third of the PCOS groups. There was also a similar increase in
body weight at both doses of HRNE. Changes in body weights of rats
for the period of treatment are given in Figure 4 .
Effect of H. rhamnoides L. on body
weight changes after disease induction. Values are expressed as mean
± SEM ( n = 5). α designated a significant
difference from N.C., while β designated a significant difference
from the PCOS group (disease control). One-way analysis of variance
(ANOVA) was used to evaluate the statistical significance between
the groups, and multiple comparison was done by Tukey’s post-hoc
test. N.C.: normal control group, HR: H. rhamnoides L., HRNE: H. rhamnoides L. nano-emulsion
formulation.
One
of the main hallmarks of PCOS is the delayed estrous cycle. To confirm
the estrous cycle regulation, vaginal cytology was done throughout
the study regularly. A change in the estrous cycle of the normal control
group was recorded at a fixed time interval, which confirms a regular
estrous cycle. All the estrous stages of normal healthy female rats
are shown in Figure 5 . In the proestrus phase, cornified nucleated epithelial cells were
predominant, whereas in the estrus phase, cells were non-nucleated
cornified epithelial. The diestrus phase mostly contained leucocytes,
while in the metestrus phase, both the cornified epithelial and nucleated
cornified cells were found.
Vaginal cytology of a normal control rat demonstrating
the different
estrous cycle phases. Vaginal smears of rats’ estrous cycle
presenting different estrous phases. (A) In the proestrus phase, cornified
epithelial cells were predominately nucleated (green arrows). (B)
Cornified epithelial cells are classed as the estrus phase ( * ). (C) The diestrus phase primarily consists of leukocytes
(red arrows). (D) Cornified epithelial cells and nucleated cornified
cells are all existing in the metestrus stage.
Rats with PCOS show delays in their normal estrous
cycle as they
remain in the diestrus phase for a prolonged time. Results are shown
in Figure 6 .
Vaginal cytology
of diseased rats (PCOS group with the diestrus
phase).
The ovaries in
the normal control group’s histopathological slides had normal
architecture, tiny to middle-sized follicles, and many corpus luteum,
granulosa cells, and follicles in numerous phases of development ( Figure 7 A). The PCOS group’s
ovary slides ( Figure 7 B) showed atretic antral follicles’ typical cystic follicles
and disorganized granulosa cell section with variable granulosa cell
thickness. Ovaries treated with letrozole have a high quantity of
cystic cavities and lack the corpus luteum. In the letrozole-treated
group, these alterations can be attributed to lower FSH and elevated
testosterone levels. However, a prominent decrease in the number and
size of cystic follicles occurs after the administration of metformin
( Figure 7 C). Group
(HR 0.5 g/kg) substantially restored the normal anatomy of the ovary
( Figure 7 D), while
group (HR 1 g/kg) showed even better results with the reduction of
cystic follicles, increasing corpus luteum and developing follicles
( Figure 7 E). Both doses
of formulation also have comparable effects like oil with betterment
of follicle development and reduction in the number of cystic follicles
( Figure 7 F,G).
Microscopic
examination of a cross section of the ovary of a rat
stained by hematoxylin–eosin. (A) Ovarian section of control
group rats exhibiting normal morphology of the rat ovary with different
stages of ovarian follicles showed atretic follicles, developing follicles,
and corpus luteum. (B) PCOS group showing typical cystic follicles
and disorganized granulosa cells. (C) Ovarian section of the metformin-treated
rat showed corpus luteum and less number of cystic follicles with
developing follicles. (D) Ovarian section of rats treated with ( H. rhamnoides L.) HR (0.5 g/kg) showed reduction
in the number of cystic follicles and more developing follicles, primary
follicles, and atretic follicles. (E) Ovarian section of HR (1 g/kg)
treated rats showed the presence of developing follicles, primary
follicles, and atretic follicles. (F) Ovarian section of HR 0.5 g/kg,
nano-emulsion showed a good number of developing, primary, and atretic
follicles. (G) Section of nano-emulsion (1 g/kg) showed corpus luteum,
primary and developing follicles, and oocyte with a lesser number
of cystic follicles. CF: cystic follicles, AF: atretic follicles,
DF: developing follicles, CL: corpus luteum, PF: primary follicles,
GF: growing follicles, Oo: oocyte.
The results of the study
clearly showed that there was fluctuation in the hormonal status after
disease induction, and significant improvement was seen with treatment.
PCOS induction significantly ( p > 0.01) lowered
the
follicle-stimulating hormone (FSH) level as compared to the control
group. Meanwhile, all the treatment groups improved the serum hormone
level. The most significant ( p > 0.001) was seen
with the HR 1 g/kg nano-emulsion (HRNE) formulation group ( Figure 8 A). PCOS also significantly
lowered the luteinizing hormone (LH) level. HRNE at both doses significantly
( p > 0.05) abridged the LH as compared to PCOS
and
similarly better effects compared to HR both groups. Results are shown
in Figure 8 B. Figure 8 C depicts that animals
with PCOS has a lower level of estrogen as compared to the normal
ones, while all the treatment groups improved the estrogen level.
The most betterment ( p > 0.01) was observed with
nano-emulsion formulation as compared to the HR group.
Effect of H. rhamnoides L. on the
serum hormone level: (A) FSH, (B) LH, (C) estrogen, (D) progesterone,
(E) testosterone, and (F) insulin. Values are expressed as mean ±
SEM ( n = 5). α designated a significant difference
from N.C., while β designated a significant difference from
the PCOS group (disease control). δ designated a significant
difference from the HR group. One-way analysis of variance (ANOVA)
was used to evaluate the statistical significance between the groups,
and multiple comparison was done by Tukey’s post-hoc test.
N.C.: normal control group, HR: H. rhamnoides L., HRNE: H. rhamnoides L. nano-emulsion
formulation.
Our results exhibited that PCOS significantly ( p > 0.001) decreased the progesterone level, and metformin
has no
effect. All the treatment groups improved the progesterone level,
and there was no significant difference between lower doses of HR
and HRNE, but 1 g/kg HRNE has comparable better effects in incrementing
the progesterone level ( Figure 8 D). The progesterone level in the serum of the disease group
was enhanced. Metformin was the most efficacious ( p > 0.001) drug in lowering the testosterone level, while all the
treatment groups also have lowered its level ( Figure 8 E). As we know, PCOS has a strong link with
insulin resistance. The similar findings were observed in our results
where the serum insulin level was markedly ( p >
0.001)
elevated in the disease group. All the treatment groups lowered the
serum insulin. Results are shown in ( Figure 8 F).
PCOS is a metabolic abnormality,
and it always disturbs the lipid profile. In this study, the total
cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein
(LDL), and triglyceride (TG) levels were determined. Disease induction
significantly elevated TC, LDL, and TG and lowered HDL. After treatment
with metformin and HR oil and HR nano-emulsion formulation, there
was a significant improvement in the HDL level and decrease in the
elevated level of TC, LDL, and TG. Additionally, HR nano-emulsion
has better effects compared with HR. Results are shown in Figure 9 .
Effect of H. rhamnoides L. on the
lipid profile. Values are expressed as mean ± SEM ( n = 5). α designated a significant difference from N.C., while
β designated a significant difference from the PCOS group (disease
control). δ designated a significant difference from the HR
group. One-way analysis of variance (ANOVA) was used to evaluate the
statistical significance between the groups, and multiple comparison
was done by Tukey’s post-hoc test. N.C.: normal control group,
HR: H. rhamnoides L., HRNE: H. rhamnoides L. nano-emulsion formulation.
Oxidative stress markers such as catalase (CAT), superoxide dismutase
(SOD), and glutathione (GSH) were assessed in the liver homogenate
of letrozole-induced female rats to check the effects of treatment
with H. rhamnoides L. The levels of
all these antioxidant enzymes were reduced by 4.67 ± 0.008 μg/mg,
66.5 ± 0.29 units/mg, and 1.85 ± 0.015 units/mg, respectively,
in the PCOS group (letrozole-treated) ( Figure 10 A–C). This clearly showed that letrozole
lowered the antioxidant enzyme level and caused oxidative stress.
Data indicated that all the treatment groups significantly ( p < 0.05) improved the level of these parameters. Letrozole
administration (1 mg/kg) in rats of PCOS groups caused a significant
rise ( p < 0.05) in the level of lipid peroxidation
markers, such as malondialdehyde (MDA) in rat livers (15.94 ±
0.01 mmol/mg). Rats in the normal control group showed a normal level
of MDA (14.352 ± 0.08 mmol/mg) ( Figure 10 D). Meanwhile, MDA levels were improved
in all the treatment groups including metformin. The most significant
effects were seen in HR nano-emulsion formulation that was comparable
with the metformin-treated group.
(A–D) Effect of H. rhamnoides L. on oxidative stress and lipid peroxidation
markers. Values are
expressed as mean ± SEM ( n = 5). α designated
a significant difference from N.C., while β designated a significant
difference from the PCOS group (disease control). δ designated
a significant difference from the HR group. One-way analysis of variance
(ANOVA) was used to evaluate the statistical significance between
the groups, and multiple comparison was done by Tukey’s post-hoc
test. N.C.: normal control group, HR: H. rhamnoides L., HRNE: H. rhamnoides L. nano-emulsion
formulation. CAT: catalase, GSH: glutathione, MDA: malondialdehyde,
SOD: superoxide dismutase.
Liver aminotransferase
was also determined from the liver tissues. There was a significant
( p < 0.05) modulation in the aspartate aminotransferase
(AST) level in the PCOS group as compared to the control group, but
all the treatments could not produce any significant change in the
ALT level after a whole treatment period. When the alanine transaminase
(ALT) and alkaline transferase levels were assessed, the PCOS group
contained significant elevated levels but treatment with plant oil
and nano-emulsion formulation significantly lowered the elevated levels
of liver enzyme markers. Results are shown in Figure 11 .
Effect of H. rhamnoides L. on liver
functioning tests (LFTs). Values are expressed as mean ± SEM
( n = 5). α designated a significant difference
from N.C., while β designated a significant difference from
the PCOS group (disease control). δ designated a significant
difference from the HR group. One-way analysis of variance (ANOVA)
was used to evaluate the statistical significance between the groups,
and multiple comparison was done by Tukey’s post-hoc test.
N.C.: normal control group, HR: H. rhamnoides L., HRNE: H. rhamnoides L. nano-emulsion
formulation, AST: aspartate aminotransferase, ALT: alanine transaminase.
Discussion
In this project, the effect
of H. rhamnoides L. (HR), also called
sea buckthorn, is evaluated for its potential
to be used for the management of PCOS in the adult female rat model. H. rhamnoides L. nano-emulsion (HRNE) was also formulated,
and its efficacy was also assessed in the same animal model. H. rhamnoides L. is a member of the family Elaeagnaceae and has a fertile history due to its traditional
medicinal uses. It is used to treat stomach ulcers, liver dysfunction,
and various conditions of skin damage. H. rhamnoides L. also possesses anti-diabetic, anti-cancer, antioxidant, hypolipidemic,
and cardio-protective activities. It is also effective in treating
endometriosis and improving the integrity of the endometrium. 25
The fruit and seed oil of H. rhamnoides L. (HR) are rich in omega-3, omega-6,
omega-7, phytosterols, antioxidants,
vitamins E and K, and carotenoids. 26 Fatty
acids and omegas are abundant in HR like palmitic acid (13.97%), stearic
acid (14.76%), oleic acid (19.94%), linoleic acid (20.357), dihydroxy
acetic acid (DHA), and omega-3 (31.10%) ( Figures 1 and 2 and Table 2 ). Total phenolic
(TPC) and flavonoid contents (TPC) of HR oil were 1713 ± 0.124
and 310 ± 0.08 μg/100 g, respectively ( Table 3 ). Additionally, DPPH radical
scavenging potential of HR oil was assessed, which had a good radical
scavenging potential with a % inhibition of 67.27 μg/mL as compared
to ascorbic acid (75.34 μg/mL) ( Table 4 ). It has a good rationale with PCOS because
in PCOS, there is background inflammation and ROS production that
might have a role in disease progression. 27 Thus, the HR oil has good DPPH activity-depicted HR potential to
reduce the disease progression and might be involved in hormonal imbalance
restoration. 2 , 27 − 29 Due to the
presence of all the above phytoconstituents and omega-3 fatty acids,
HR showed good antioxidant potential. Antioxidant potential is depicted
with good DPPH values. These substances work together to safeguard
cell membranes and improve cell regeneration. These antioxidant substances
also reduce reactive oxygen species (ROS) production that play a role
in inflammatory episodes. These inflammatory episodes play a role
in worsening of the PCOS symptoms. 2 , 19
HR nano-emulsion
was prepared, and its purpose was to enhance its
bioavailability and solubility. DSC of the nano-emulsion showed no
endothermic peak, indicating the uniform distribution of HR oil, and
TGA of the final formulation showed two-step degradation. Characteristic
peaks of HR oil also shown in the FTIR spectra of nano-emulsion indicated
the chemical stability of formulation ( Figure 3 A–C). All the results of HR oil and
HR nano-emulsion are compared and discussed in the upcoming sections.
The disease was induced by the administration of letrozole (1 mg/kg)
for 5 weeks. 28 Disease induction was confirmed
by vaginal smear analysis ( Figure 5 ), and weight variations were recorded ( Table 4 and Figure 4 ). Vaginal smear analysis revealed the confirmation
of the disease in the PCOS group as the number of leukocytes increased
plentifully presenting the diestrus stage of the estrous cycle ( Figure 5 ). Rats with PCOS
stayed in their diestrus stage for a persistent period. 19 , 28 Meanwhile, the treatment with H. rhamnoides L. obliterates the abnormality of the estrous cycle and regulates
the cyclicity ( Figure 6 ).
Moreover, histopathology of the ovaries of the normal control
group
revealed the presence of normal architecture, tiny to middle-sized
follicles, and many corpus luteum, granulosa cells, and developing
follicles ( Figure 7 A). The PCOS group’s ovary slides ( Figure 7 B) showed atretic antral follicles and are
cystic in nature. However, a prominent decrease in the number and
size of cystic follicles occurs after the administration of metformin
( Figure 7 C). Group
(HR 0.5 g/kg) substantially restored the normal anatomy of the ovary
( Figure 7 D), while
group (HR 1 g/kg) showed even better results with the reduction of
cystic follicles, increasing corpus luteum and developing follicles
( Figure 7 E). Both doses
of formulation (HR nano-emulsion) also have comparable effects like
oil with maturation of cystic follicles into developing follicles
( Figure 7 F,G).
The hypothalamic gonadotropin-releasing hormone (GnRH) is in charge
of pituitary hormone control, including FSH and LH. Unfortunately,
in PCOS, normal control is disrupted, and an LH surge occurs, depleting
FSH and altering the LH/FSH ratio. 2 These
gonadotrophin irregularities are aggravated by interrupting the HPA
feedback mechanism. The ovarian cytochrome P450 17A 1 (CYP45017A 1 ) gene was over-expressed, and it ultimately enhanced the
level of the 17-hyroxylase enzyme, which might be responsible for
the over-production of androgens from progesterone. All of these abnormalities
are due to the abnormal triggering of the P13k/Akt pathway. More testosterone
is created as a result of this spike, increasing anti-Müllerian
hormone levels (AMH). Many follicles are present, but their development
is halted, and they are unable to mature sufficiently to cause ovulation,
as shown in Figure 7 B. The overall impact on the hormone level is reduced FSH and increased
level of LH ( Figure 8 B,C). This LH surge deteriorated the ovarian architecture with more
cystic and less mature follicles. Estrogen and progesterone levels
also reduced, while testosterone and insulin levels increased ( Figure 8 D–F).
Hyperinsulinemia has multiple reasons such as impairment of beta
cells in the pancreas and peripheral insulin resistance. This type
of impairment has a strong family tendency, but the actual appearance
of this syndrome must have a strong impact from various environmental
factors. Metformin is one of the most used drugs to overcome insulin
resistance. In our study, we also observed similar findings; metformin
lowered the serum insulin level significantly ( Figure 8 F). Thus, improving insulin tolerance may
play a role in management of PCOS. Both doses of HR oil and HRNE have
a significant effect in the improvement of the FSH level, and they
also played a pivotal role in normalizing the LH surge that is necessary
for the rectification of LH/FSH surge. Thus, cumulation will improve
the follicle maturing ability of ovaries ( Figure 8 A,B). Moreover, plant oil and its formulation
also have beneficial effects on normalizing the progesterone, estrogen,
and testosterone levels, and in this way, they improved ovarian functionality.
Thus, there were more mature follicle corpus luteum and lesser number
of immature cystic follicles ( Figure 8 C–E).
Omega-3 DHA (docosahexaenoic acid)
is classified as polyunsaturated
fatty acids (PUFAs). DHA omega-3 has the potential to be an antioxidant,
anti-obesity, and insulin sensitizer. 30 DHA is also helpful in balancing the hormonal profile of PCOS patients. 31 Omega-3 DHA boosts the secretion of the anti-inflammatory
adiponectin and improves insulin sensitivity while decreasing the
production of pro-inflammatory cytokines like tumor necrosis factor
(TNF) and IL-6. 32 PCOS is characterized
by insulin resistance, obesity, and cardiometabolic changes like dyslipidemia,
diabetes, and hypertension that typically appear in PCOS individuals
after the age of 40. 33
PCOS is a
metabolic abnormality, and it has a bad impact on the
weight and lipid profile. PCOS increases total cholesterol (TC), LDL,
and TG, while it decreases the HDL level significantly. 6 PCOS may lead to obesity, which also plays a
role in hypertriglyceridemia. 34 All the
doses of HR oil and formulation have a significant effect in improvement
of HDL and lowered the levels of TC, LDL, and TG. The most significant
improvement was seen with the highest dose of formulation (HRNE 1
g/kg). H. rhamnoides L. oil and formulation
HRNE show a positive effect in the regulation of the lipid profile
( Figure 9 ). The most
prominent effects were observed with HRNE 1 g/kg. Likewise, metformin,
a well-known sensitizing insulin, also has a similar type of lipid
profile improvement. These findings are persistent with previous reports
that HR is effective in reducing weight gain as well as lowering the
TC and TG. 6 , 35
PCOS patients have hyperinsulinemia
that may also cause hyperglycemia,
possibly due to insulin resistance. In PCOS patient’s, the
proposed mechanism behind hyperglycemia, dyslipidemia, and insulin
resistance comorbidities is an increase in the visceral adipose tissue.
An excess of macronutrients in the visceral adipose tissues stimulates
the adipose tissues to release inflammatory mediators such as IL-6
and TNF-α, disposing oxidative stress and pro-inflammatory state. 36 Omega-3 (DHA) inhibits the release of TNF-α
and other inflammatory mediators, so the anti-inflammatory and anti-diabetic
effects of H. rhamnoides L. are justified
by the presence of these phytoconstituents. 37
H.
rhamnoides L. oil in part avoids
UV-induced ROS generation and improves the level of antioxidant enzymes
such as glutathione (GSH), thioredoxin (Trx), and vitamins A and E.
Oxidative stress is also involved in the etiology of PCOS, and the
level of antioxidant decrease is frequent in PCOS females. Oxidative
stress is caused by an imbalance of oxidants and antioxidants. PCOS
is associated with an oxidative condition. Letrozole is used for PCOS
induction, and it has a bad impact on antioxidant markers such as
catalase (CAT), superoxide dismutase (SOD), and glutathione (GSH)
in the body. Similar findings were seen in our study, where levels
of SOD, CAT, and GSH were perturbed ( Figure 10 ). Additionally, the lipid peroxidation
marker MDA was increased. 38 HR oil along
with its formulation (HRNE) improved SOD, CAT, and GSH and lowered
the level of MDA ( Figure 10 A–D). The most significant improvement was observed
with formulation. All the phytochemicals present in HR such as omega-3,
palmitic acid, stearic acid, linoleic acid, and oleic acid 39 have an excellent antioxidant potential. 40 Thus, the antioxidant potential of oil HR might
be due to the presence of these phytoconstituents. One more experiment
was included to assess the effects of HR and HRNE on liver functioning
tests (LFTs). PCOS disturbed the level of LFTs, but HR and HRNE improved
these parameters. However, we did not observe any significant toxic
effects of HR and HRNE (HR nano-emulsion) on ALT, AST, and alkaline
phosphatase ( Figure 11 ).
Conclusions
Herein, it can be concluded
that the results of this study revealed
that H. rhamnoides L. oil (HR) and
its formulation (nano-emulsion) at both doses effectively restored
the hormonal imbalance in the letrozole-induced PCOS rat model. Additionally,
HR and HRNE improved ovarian health with mature and developing follicles.
This was possible due to the presence of various phytochemicals that
reduced lipid peroxidation and ROS production, reduced underground
inflammation and weight control, and improved insulin sensitivity.
HRNE efficacy was more significant as compared to HR, which might
be due to its better bioavailability.
Experimental
H. rhamnoides L. oil
was courteously provided by Saffron Pharmaceuticals PVT. Ltd., Faisalabad,
Pakistan. It was extracted from plant berries, which were collected
from the northern areas of Pakistan.
Fatty
acid composition of the H. rhamnoides oil was analyzed by using GC-FID (GC-FID, Perkin Elmer). The IUPAC
standard protocol was applied, which is based upon derivatization
of fatty acids into FAMEs (fatty acid methyl esters) (IUPAC, 1987).
FAME was analyzed on a gas chromatograph model Clarus-580 (Perkin
Elmer), fitted with a SP-2330 (SUPLECO, Inc., Bellefonte, PA, USA)
methyl lignoserate-coated (film thickness, 0.20 μm) polar capillary
column (30 m × 0.32 mm) and a flame ionization detector. Oxygen-free
nitrogen was used as a carrier gas at a flow rate of 3 mL min.
Other conditions were as follows: initial oven temperature, 180 °C;
ramp rate, 5 °C/min; final temperature, 220 °C; injector
temperature, 230 °C; detector temperature, 240 °C; FAMEs
were identified by comparing their relative and absolute retention
times with those of authentic standards of FAMEs (Sigma Chemical Co.,
St Louis, MO, USA). The quantification was done using the external
standard method by plotting the concentration against the peak areas
of different standards concentrations. The fatty acid composition
was reported as a relative percentage of the total peak area. 13
Gas chromatography by flame ionization
(GC-FID) is a widely used
method for the identification of lipids and fatty acids in oils. GC-FID
of H. rhamnoides L. oil was performed
by forming its methyl ester using a Restek (RTX-1) (30 m × 0.25
mm i.d.) 100% dimethyl polysiloyane column, with an FID detector 220
temperature. An HP 7673 autosampler and a split–split less
injector (split ratio of 1:15) were used to inject the samples (1
μL). The oven’s temperature was set at 120 °C; ABS
nitrogen, oxygen, and hydrogen gases were utilized as the carrier
gas and an inlet pressure of 175 kPa. The temperatures of the injector
and detector were operated at 120 and 220 °C, respectively, and
a column flow of 1 mL/min was achieved. HP 3365 Series II ChemStation
software (version A.03.34) was used to collect the data. The samples
were all tested in triplicate. It has been observed that palmitic,
docosahexaenoic acid (DHA), oleic acids, and linoleic acids were prevalent
in the fatty acids quantified using myristinic acid as a standard. 14
At room temperature, methanol and KOH
(potassium hydroxide) were
combined to create methyl ester. After 1 h of stirring, the mixture
was allowed to settle, and the product of the reaction was simply
decanted into two parts. The fatty acid methyl ester (FAME) upper
layer was removed to further purify it by washing with water (10 times).
The volatile part was then removed under reduced pressure, while the
FAME was kept standing over magnesium sulfate after being dissolved
in dichloromethane. Methanol, oil, and KOH were used in the transesterification
process in a total molar ratio of 7:1:0.01. 15 , 16
H. rhamnoides L. nano-emulsion was formulated by using various concentrations
of the surfactant (Tween 60 and 80) and co-surfactant (PEG 400) by
adding these into HR and cinnamon oil in 3:2:1:1, and then, its effect
in treatment of PCOS was evaluated by administering to letrozole-induced
PCOS rats.
The prepared nano-emulsion was evaluated by FTIR,
DSC, and TGA. Thermal stability of the HR oil in nano-emulsion was
evaluated by DSC weight loss of nano-emulsion, and the formulation
under different temperature conditions was also evaluated. The interaction
of HR oil with other used oils and excipients was checked by FTIR.
Thirty-five healthy female Wistar albino rats, weighing 100–130
g, were acquired and housed in the animal facility of the Government
College University Faisalabad. Standard laboratory conditions were
maintained (10/14 h light/dark cycle, 25–30 °C, 45–55%
relative humidity). Rats were given a standard laboratory diet and
water ad libitum. Animals were handled according to ARRIVE guidelines.
Study protocols were approved by the Ethical Review Committee of Government
College University Faisalabad, and ref no. (GCUF/ERC/ 52.1) was obtained.
Animals
were allowed for a 1 week adaptation period. Letrozole (1 mg/kg) was
used to induce the PCOS. Letrozole suspension was prepared by dissolving
letrozole in 0.5% of CMC carboxymethyl cellulose solution. Letrozole
suspension was administered to rats for 5 weeks for the induction
of PCOS. To confirm the disease induction, estrous cycle monitoring
and weight changes were recorded weekly. To determine the stages of
the estrous cycle, vaginal cytology was performed daily, which was
indicated by the ratio of cornified, leukocyte, and epithelial cells
under light microscopy. 17
A complete randomized design
was used for animals’ division into groups. There were seven
groups, and each group contained five animals. Groups were labeled
as normal control (N.C.), diseased (PCOS), standard (metformin), HR
(0.5 g/kg), HR (1 g/kg), HRNE (0.5 g/kg), and HRNE (1 g/kg). All the
drugs were administered orally through gavage. A vaginal smear was
observed daily, and weight changes were recorded weekly.
The dosage schedule
for the experimental designs of H. rhamnoides L. is explained in Table 1 .
Estrous cycle
stages were determined by analyzing the vaginal smear. 18 After completion of the treatment duration,
rats were euthanized and blood was taken by cardiac puncture. Serum
was separated by centrifugation to identify hormonal evaluation such
as luteinizing hormone (LH), follicle-stimulating hormone (FSH), serum
insulin, progesterone, estrogen, and testosterone. The liver functioning
test (LFT) and lipid profile were also examined. Histopathology of
rat ovaries was also performed to visualize the effect on follicular
cysts. Oxidative stress markers were also tested by antioxidant assays
on liver homogenate.
To prepare vaginal smears of rats, each animal was
removed from the cage and the vaginal hole was opened carefully. A
damp cotton gauze moistened with distilled water was placed into the
vagina of the rat. A cotton swab was rotated softly for a while and
removed. A smear was created on a cleaned grease-free glass slide
with the help of this cotton sab. The slide was then air-dried, washed
with 10% methanol solution, and stained with a dye such as methylene
blue. It should be cleaned with distilled water, allowed to air-dry,
and then examined using a binocular microscope (accuscope) to recognize
the various stages of the estrous cycle. The estrous cycle comprises
four phases, such as proestrus, estrus, metestrus, and diestrus. 18
Animals
were euthanized after completion of the blood drawing procedure. Female
rats were dissected, and ovaries were removed by following the standard
procedure, according to ARRIVE guidelines. Ovaries from each female
rat were fixed in 4% paraformaldehyde (PFA) and further in 20% sucrose
solution. Later, tissue embedding was done in Tissue-Tek (O.C.T. compound;
Sakura) and frozen at – 80 °C overnight, and tissues were
cut into sections (6 μm thickness). Hematoxylin and eosin (H&E)
stain was used to stain the tissues, according to the standard histological
procedures. Ovarian morphology was examined in a way that the glass
slide was mounted with every 12th section. All the antral follicles
and corpora lutea were counted. The follicle diameter was calculated
as the mean distance between opposite basal membrane portions, while
the wall thickness was calculated as the sum of theca internal and
granulosa cell layers. All large fluid-filled cysts with an attenuated
granulosa cell layer and thickened theca cell layer were considered
as cystic follicles. 19
For the
hormone analysis radioimmunoassay (RIA) and enzyme-linked immune-sorbent
assay (ELISA), kit methods were used on the blood serum of rats. Blood
samples were collected by cardiac puncture, and then, the serum was
separated by cold centrifugation at 3000 rpm for 5 mins. Serum follicle-stimulating
hormone (FSH; mIU/mL), progesterone (ng/dL), and testosterone (ng/dL)
levels were measured by the radioimmunoassay (RIA; Gamma counter)
utilizing the kit of Beckman Coulter, Inc. USA, while serum luteinizing
hormone (LH; mIU/mL) concentration was determined by the enzyme-linked
immune-sorbent assay (ELISA) method using the kit of Pointe Scientific
Inc. USA. Serum estrogen (pg/mL) was assessed by using the kit of
ALPCO, USA, and serum insulin (ulU/mL) was determined by using the kit of Calbiotech Inc., USA.
Analysis of total serum cholesterol and triglycerides
was done spectrometrically. Serum HDL and LDL levels were analyzed
enzymatically (DiaSys Diagnostic System GmbH, Germany). Likewise,
different markers of liver function tests, i.e., levels of ALT, AST,
and ALP, along with the total and direct bilirubin levels were also
evaluated. The liver functioning test (LFT) was also performed spectrophotometrically
on a semi-automated chemistry analyzer (microlab-300).
Tissue homogenate was prepared by using 0.1 M phosphate buffer
(pH 7.4) and 1 g of tissue from the liver and grinded it with a tissue
homogenizer. The phosphate buffer contained 10 mM potassium chloride,
1 mmol of ethylene diamine tetra-acetic acid (EDTA), 0.25 M sucrose,
and 1 mM phenylmethylsulfonylfluoride. Then, the mixture was centrifuged
at 800 rpm at 4 °C for 30 min to obtain the supernatant. The
supernatant solution was separated and used for the assessment of
antioxidant parameters (CAT, MDA, SOD, and GSH).
DPPH analysis was done according to established protocols and already
published in our previous study. 14 , 20 , 21 The capacity to scavenge the DPPH radical was calculated
by the following equation: where AB is the absorbance of blank at 0 min
and AA is the absorbance of the sample to be tested at 30 min.
The total phenolic content of HR was measured by using the method
described by Shukla et al. 22 and the already
published methods in our previous study. 23 The TPC of all the samples was determined using the following formula: where V is the volume of
the extract in mL, m is the mass of the extract in
grams, C is the total phenolic content mg GAE/g dry
extract, and c is the gallic acid concentration calculated
from the calibration curve (mg/mL).
The total flavonoid content was measured as quercetin equivalent
by making its standard curve (10–130 ppm). The TFC was determined
according to the standard protocol and already published studies. 21 , 24
Data was presented
as mean ± SEM. Statistical analyses were performed with a one-way
analysis of variance (ANOVA), and Tukey’s multiple comparison
test was used to evaluate the hormonal differences among the groups.
GraphPad Prism version 8.02 was used for all the statistical analyses.
A two-way analysis of variance with repeated measures for a time was
used to test the significance of various groups. The data was considered
statistically significant if p < 0.05.
Introduction
PCOS (polycystic ovarian
syndrome) is a common endocrine ailment
that affects women during their reproductive age. PCOS may cause hyperandrogenism
and oligo-anovulation, both of which have significant physiological,
psychological, and social consequences. 1 Women with PCOS are prone to metabolic abnormalities, with multiple
complications. There has been an increase in awareness of this illness
in the general population and medical communities in recent years. 2 Because of the variability of symptoms, the concept
of PCOS has been debated in various fields of medicine such as in
internal medicine, gynecology, and psychiatry. The recent research
explored a new diagnostic marker for PCOS blood organic solvents (VOCs)
such as 4-ethylphenol and capric acid; thus, additional screening
methods should be included for PCOS diagnosis. 3 As a result, elucidating the origins of the PCOS and distinguishing
pathological abnormalities from secondary environmental disturbances
remain persistent challenges not only for clinicians but also for
researchers. 4
PCOS is a prevalent,
complicated, and diverse endocrine condition
that affects 5–10% of women of reproductive age. This condition
is characterized by oligomenorrhea, amenorrhea, anovulation, a large
number of antral follicles, hypersecretion of the luteinizing hormone
(LH) but with lesser or similar FSH levels, hirsutism, and hyperandrogenemia.
Majority of patients also have metabolic issues, such as obesity,
dyslipidemia, and insulin resistance. 5 Women
with PCOS are more likely to have reproductive problems, and major
proportions have metabolic dysfunction, which increases their risk
of developing type II diabetes and cardiovascular disease. Insulin
resistance and compensatory hyperinsulinemia are common in women with
PCOS, with rates as high as 95% in obese women. Hyperinsulinemia may
increase aberrant androgen production as well as alter folliculogenesis
and menstrual cyclicity; all of these are hallmarks of PCOS. 6
Hippophae rhamnoides L. (HR), a
member of the family Elaeagnaceae commonly called
sea buckthorn oil, also has a history of its traditional medicinal
use to treat stomach ulcers, liver dysfunction, and various conditions
of skin damage due to the presence of flavonoids, phenols vitamins,
and minerals. 7 The sea buckthorn plant,
also known as the Chinese medicinal herb, is indigenous to Siberia,
Central Asia, China, Mongolia, and the Caucasus regions. 7 , 8 Currently, H. rhamnoides L. oil is
used in skincare products because of its possible advantageous effects
on the skin. The presence of flavonoids, polyphenols, polysaccharides,
sterols, phenols, and tannins will mainly exert a favorable effect
in alleviating PCOS-related symptoms. 9 All
the plant parts possess phytoconstituents with potential antioxidant
properties. 8 This is why all the tested
sea buckthorn products had high antioxidant activity. In 100% sea
buckthorn oil, the highest levels of total polyphenols (204.26 mg
GAE/g), flavonoids (30.00 mg QE/g), and carotenoids (0.34 mg/g) were
found. 10
Because H.
rhamnoides L. (sea buckthorn)
oil has a long history of use as an anti-diabetic, antioxidant, hypolipidemic
agent, anticancer, in endometriosis and vaginal atrophy, cardioprotective,
anti-platelets, anti-viral, anti-bacterial, and anti-inflammatory
agent, it would be worthwhile to investigate its potential in PCOS
therapy. This study explores the efficacy of H. rhamnoides L. in the treatment of rats with letrozole-induced PCOS. H. rhamnoides L. is oil, and most of the time, solubility
and dissolution in gastrointestinal fluids are big problems. 11 Various formulations are in practice to overcome
these solubility-related problems of various drugs to enhance bioavailability.
One of these types of techniques is nano-emulsion formulation, which
is used to enhance the dissolution and bioavailability of various
drugs. Nano-emulsion-based formulation is a good choice for oil-based
herbal products. 12 H. rhamnoides L. nano-emulsion (HRNE) was also formulated. The aims and objectives
of the study were to evaluate the efficacy of HR and its nano-emulsion
(HRNE) in letrozole-induced PCOS female adult rats. Additionally,
it was also expanded to assess whether nano-emulsion (HRNE) has better
efficacy as compared to HR oil.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.